Published in Handb Exp Pharmacol on January 01, 2012
Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proc Natl Acad Sci U S A (2013) 1.31
The touchscreen operant platform for testing learning and memory in rats and mice. Nat Protoc (2013) 1.31
The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry (2014) 1.14
Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents. Neuron (2015) 1.10
Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents. ACS Chem Neurosci (2014) 1.06
Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A "central hub" in schizophrenia pathophysiology? Schizophr Res (2014) 1.06
Microglial dysregulation in psychiatric disease. Clin Dev Immunol (2013) 1.01
Major channels involved in neuropsychiatric disorders and therapeutic perspectives. Front Genet (2013) 0.97
Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications. Int J Biol Sci (2013) 0.96
Reviewing the ketamine model for schizophrenia. J Psychopharmacol (2013) 0.96
Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis. Nat Rev Neurosci (2016) 0.94
Pathological Basis for Deficient Excitatory Drive to Cortical Parvalbumin Interneurons in Schizophrenia. Am J Psychiatry (2016) 0.93
Trans-synaptic zinc mobilization improves social interaction in two mouse models of autism through NMDAR activation. Nat Commun (2015) 0.90
A selective review of glutamate pharmacological therapy in obsessive-compulsive and related disorders. Psychol Res Behav Manag (2015) 0.89
Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system. Front Psychiatry (2014) 0.85
Holding multiple items in short term memory: a neural mechanism. PLoS One (2013) 0.84
Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.84
Impact of structural aberrancy of polysialic acid and its synthetic enzyme ST8SIA2 in schizophrenia. Front Cell Neurosci (2013) 0.83
Elevated homocysteine level in first-episode schizophrenia patients--the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse. Metab Brain Dis (2014) 0.83
Design, synthesis, and structure-activity relationship of a novel series of GluN2C-selective potentiators. J Med Chem (2014) 0.83
Computational neuropsychiatry - schizophrenia as a cognitive brain network disorder. Front Psychiatry (2014) 0.82
The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment. Curr Neuropharmacol (2014) 0.82
Effects of prefrontal cortex and hippocampal NMDA NR1-subunit deletion on complex cognitive and social behaviors. Brain Res (2014) 0.81
Cortical synaptic NMDA receptor deficits in α7 nicotinic acetylcholine receptor gene deletion models: implications for neuropsychiatric diseases. Neurobiol Dis (2013) 0.81
In Sickness and in Health: Perineuronal Nets and Synaptic Plasticity in Psychiatric Disorders. Neural Plast (2015) 0.79
Impact of glutamate levels on neuronal response and cognitive abilities in schizophrenia. Neuroimage Clin (2014) 0.79
A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses. J Pharmacol Exp Ther (2014) 0.79
Conceptualization and treatment of negative symptoms in schizophrenia. World J Psychiatry (2015) 0.78
Weaving a Net of Neurobiological Mechanisms in Schizophrenia and Unraveling the Underlying Pathophysiology. Biol Psychiatry (2016) 0.78
Altered functional connectivity links in neuroleptic-naïve and neuroleptic-treated patients with schizophrenia, and their relation to symptoms including volition. Neuroimage Clin (2014) 0.78
Role for the M1 Muscarinic Acetylcholine Receptor in Top-Down Cognitive Processing Using a Touchscreen Visual Discrimination Task in Mice. ACS Chem Neurosci (2015) 0.77
Homozygous Deletion of Glutathione Peroxidase 1 and Aldehyde Dehydrogenase 1a1 Genes Is Not Associated with Schizophrenia-Like Behavior in Mice. J Biochem Pharmacol Res (2013) 0.77
Maternal immune activation alters glutamic acid decarboxylase-67 expression in the brains of adult rat offspring. Schizophr Res (2016) 0.77
Neuregulin-2 ablation results in dopamine dysregulation and severe behavioral phenotypes relevant to psychiatric disorders. Mol Psychiatry (2017) 0.76
Sex differences in GABAergic gene expression occur in the anterior cingulate cortex in schizophrenia. Schizophr Res (2015) 0.76
Subchronic phencyclidine treatment in adult mice increases GABAergic transmission and LTP threshold in the hippocampus. Neuropharmacology (2015) 0.76
Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia. Nutrients (2015) 0.76
Preliminary investigation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one derivatives as a novel series of mGlu5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia. Bioorg Med Chem Lett (2015) 0.75
State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects. Neuropharmacology (2015) 0.75
Axonal Type III Nrg1 Controls Glutamate Synapse Formation and GluA2 Trafficking in Hippocampal-Accumbens Connections. eNeuro (2017) 0.75
Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs. Front Pharmacol (2016) 0.75
Enhancing NMDA Receptor Function: Recent Progress on Allosteric Modulators. Neural Plast (2017) 0.75
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med (2005) 28.99
Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature (2008) 20.31
mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science (2010) 10.97
Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry (2006) 9.44
Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature (1987) 8.89
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry (1994) 8.88
Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry (1991) 8.10
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med (2007) 7.24
Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry (1995) 7.19
Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry (2000) 6.91
Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet (2008) 6.71
Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A (2001) 6.68
Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proc Natl Acad Sci U S A (2009) 6.09
Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology. Schizophr Res (2008) 5.99
Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) (2001) 5.67
Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci (2008) 5.12
Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. Am J Med Genet (2000) 5.07
Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci (2008) 4.91
Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) (2001) 4.52
Translating developmental time across mammalian species. Neuroscience (2001) 4.39
NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci (2007) 4.35
A review of diffusion tensor imaging studies in schizophrenia. J Psychiatr Res (2005) 4.34
Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med (2006) 4.00
The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry (2005) 3.92
A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry (2003) 3.77
Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science (1998) 3.70
The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol (1983) 3.69
Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science (1988) 3.54
D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release. Proc Natl Acad Sci U S A (1995) 3.51
Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry (2006) 3.45
Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch Gen Psychiatry (2000) 3.44
A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc Natl Acad Sci U S A (1998) 3.33
Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science (2007) 3.32
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry (2008) 3.30
Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J Neurol Neurosurg Psychiatry (1998) 3.26
Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci (2008) 3.22
Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. Am J Psychiatry (2008) 3.16
Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission. Proc Natl Acad Sci U S A (1999) 3.15
Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A (2002) 3.11
A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry (2001) 3.10
Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology (1978) 3.08
Modulation of neuronal migration by NMDA receptors. Science (1993) 3.07
NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature (2005) 2.92
Atypical antipsychotics: mechanism of action. Can J Psychiatry (2002) 2.91
DTI and MTR abnormalities in schizophrenia: analysis of white matter integrity. Neuroimage (2005) 2.84
Synaptogenesis in the prefrontal cortex of rhesus monkeys. Cereb Cortex (1994) 2.68
Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry (1959) 2.66
Two forms of the gamma-aminobutyric acid synthetic enzyme glutamate decarboxylase have distinct intraneuronal distributions and cofactor interactions. J Neurochem (1991) 2.66
The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci (2001) 2.61
DNA copy-number analysis in bipolar disorder and schizophrenia reveals aberrations in genes involved in glutamate signaling. Hum Mol Genet (2006) 2.50
Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest (2004) 2.46
Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry (2003) 2.39
Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch Gen Psychiatry (2004) 2.37
Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res Rev (2006) 2.36
D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry (1998) 2.36
NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci (1996) 2.35
Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry (2008) 2.33
Impulse activity and the patterning of connections during CNS development. Neuron (1990) 2.32
Purification of serine racemase: biosynthesis of the neuromodulator D-serine. Proc Natl Acad Sci U S A (1999) 2.27
Increased cortical kynurenate content in schizophrenia. Biol Psychiatry (2001) 2.27
Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry (2000) 2.26
Local circuit neurons immunoreactive for calretinin, calbindin D-28k or parvalbumin in monkey prefrontal cortex: distribution and morphology. J Comp Neurol (1994) 2.25
Long-term potentiation in the hippocampus involves activation of N-methyl-D-aspartate receptors. Brain Res (1984) 2.21
A single dominant gene can account for eye tracking dysfunctions and schizophrenia in offspring of discordant twins. Arch Gen Psychiatry (1988) 2.21
Myelination of cortical-hippocampal relays during late adolescence. Schizophr Bull (1989) 2.19
Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology (2001) 2.18
Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. Mol Psychiatry (2004) 2.11
Mutational analysis of the glycine-binding site of the NMDA receptor: structural similarity with bacterial amino acid-binding proteins. Neuron (1994) 2.11
Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse (1987) 2.08
A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc Natl Acad Sci U S A (1998) 2.00
Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology (1999) 1.97
Principles of long-term dynamics of dendritic spines. J Neurosci (2008) 1.96
Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum Mol Genet (2004) 1.95
Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG1+/- knock-outs compared with wild-type mice. J Neurosci (2007) 1.94
Two human glutamate decarboxylases, 65-kDa GAD and 67-kDa GAD, are each encoded by a single gene. Proc Natl Acad Sci U S A (1992) 1.93
Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am J Psychiatry (2000) 1.93
Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry (2003) 1.93
A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J Neurosci (2006) 1.93
Reduced dendritic spine density in auditory cortex of subjects with schizophrenia. Neuropsychopharmacology (2008) 1.93
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett (2001) 1.89
A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia. Schizophr Res (2002) 1.87
Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology (2007) 1.86
Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biol Psychiatry (2002) 1.83
Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch Gen Psychiatry (2004) 1.82
Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. J Neurosci (2008) 1.80
What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull (2008) 1.80
Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry (1993) 1.80
Functional comparison of D-serine and glycine in rodents: the effect on cloned NMDA receptors and the extracellular concentration. J Neurochem (1995) 1.79
Endogenous D-serine in rat brain: N-methyl-D-aspartate receptor-related distribution and aging. J Neurochem (1993) 1.78
Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb Cortex (2002) 1.77
Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry (2000) 1.75
Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry (1995) 1.71
Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci U S A (1998) 1.71
Serine racemase: activation by glutamate neurotransmission via glutamate receptor interacting protein and mediation of neuronal migration. Proc Natl Acad Sci U S A (2005) 1.68
Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci (1992) 1.68
Composition of the synaptic PSD-95 complex. Mol Cell Proteomics (2007) 1.68
A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr Res (2006) 1.67
Cortical glutamatergic markers in schizophrenia. Neuropsychopharmacology (2005) 1.67
Critical appraisal of DNA microarrays in psychiatric genomics. Biol Psychiatry (2006) 1.66
Schizophrenia and the alpha7 nicotinic acetylcholine receptor. Int Rev Neurobiol (2007) 1.65
Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia. Dialogues Clin Neurosci (2010) 0.94